- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06821113
Vale+Tú Salud: Corner-Based Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19
August 19, 2025 updated by: Maria Eugenia Fernandez-Esquer, The University of Texas Health Science Center, Houston
Vale+ Tu Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID 19
The purpose of this study is to determine the cultural, socioeconomic, inter/personal and work-related factors that influence COVID 19 mitigation practices including social distancing, hand-washing and Personal protective equipment (PPE) use, to adapt, implement, and test Vale+Tú Salud in a cluster randomized trial to assess the extent to which LDL report increased adherence with COVID 19 mitigation practices 1 month post intervention and to promote Vale+Tú Salud just-in-time results and increase its capacity to rapidly disseminate findings among groups that serve LDL and other Latino immigrants.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maria E Fernandez-Esquer, PhD
- Phone Number: (713) 500-9657
- Email: Maria.E.Fernandez-Esquer@uth.tmc.edu
Study Contact Backup
- Name: Cesar L Pinzon-Gomez
- Phone Number: (713) 500-9614
- Email: Cesar.L.PinzonGomez@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Maria E Fernandez-Esquer, PhD
- Phone Number: 713-500-9657
- Email: Maria.E.Fernandez-Esquer@uth.tmc.edu
-
Contact:
- Cesar L Pinzon-Gomez
- Phone Number: (713) 500-9614
- Email: Cesar.L.PinzonGomez@uth.tmc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Self-identify as Hispanic or Latino
- Be present at the corner for the purposes of looking for work
Exclusion Criteria:
- Have not been previously hired to work at a corner
- Symptoms of COVID-19 in the previous 48 hours
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care
|
Participants will receive a COVID-19 prevention flyer and social resources list only
|
|
Experimental: COVID-19 Group Problem Solving and booster call
|
Participants will have three core components to be delivered at the corner by trained data collectors.
Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a personal commitment called "Mi Promesa" to implement COVID mitigation practices.
Navigation Component will consist of providing information and linking LDLs with social service providers and the "Multiplicador de salud"/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support.
Participants will receive a COVID-19 prevention flyer and social resources list only
Participants in this group will also receive a "booster phone call" 10 to 15 days after the small group intervention to provide brief prompts to encourage participants to act on their personal commitments and encourage them to seek community resources.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in COVID-19 vaccination status as assessed by a survey
Time Frame: Baseline, 4 weeks post intervention
|
Baseline, 4 weeks post intervention
|
|
Change in hand washing frequency as assessed by a survey
Time Frame: Baseline, 4 weeks post intervention
|
Baseline, 4 weeks post intervention
|
|
Percentage of participants who report contacting the gold card agency
Time Frame: Baseline, 4 weeks post intervention
|
Baseline, 4 weeks post intervention
|
|
Percentage of participants who report contacting the agency for assistance to get food
Time Frame: Baseline, 4 weeks post intervention
|
Baseline, 4 weeks post intervention
|
|
Percentage of participants who report contacting the agency for assistance for health care resources
Time Frame: Baseline, 4 weeks post intervention
|
Baseline, 4 weeks post intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Maria E Fernandez-Esquer, PhD, The University of Texas Health Science Center, Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 3, 2025
Primary Completion (Estimated)
November 1, 2025
Study Completion (Estimated)
November 1, 2025
Study Registration Dates
First Submitted
February 7, 2025
First Submitted That Met QC Criteria
February 7, 2025
First Posted (Actual)
February 11, 2025
Study Record Updates
Last Update Posted (Estimated)
August 26, 2025
Last Update Submitted That Met QC Criteria
August 19, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia, Viral
- Pneumonia
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- COVID-19
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
- HSC-SPH-20-1389 (Phase 3)
- 1R01MD016328-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
RSUP PersahabatanCompletedPost COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID Syndrome Long CovidIndonesia
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
Clinical Trials on COVID-19 Group Problem Solving
-
The University of Texas Health Science Center,...National Institute on Minority Health and Health Disparities (NIMHD)Completed
-
The University of Texas Health Science Center,...National Institute on Minority Health and Health Disparities (NIMHD)Completed
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Istanbul UniversityCompleted
-
University of OttawaOttawa Hospital Research InstituteActive, not recruiting
-
Washington University School of MedicineNurses for Newborns FoundationCompletedPost-partum DepressionUnited States
-
Rosalind Franklin University of Medicine and ScienceMedical College of Wisconsin; Children's Hospital and Health System Foundation...UnknownInflammatory Bowel DiseaseUnited States
-
VA Office of Research and DevelopmentCompletedDepression | AnxietyUnited States
-
Boston Medical CenterCenters for Disease Control and PreventionCompletedChild AbuseUnited States
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedMild Cognitive ImpairmentUnited States